Selected research
Industry Research
Anti-Suicide Drug Industry Research Report 2026
Market perspective
The global Anti-Suicide Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-Suicide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-Suicide Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-Suicide Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-Suicide Drug include Allergan plc, H. Lundbeck A/S, NeuroRx, Inc., AstraZeneca plc, GlaxoSmithkline plc, Pfizer, Inc., Eli Lilly and Company, Merck & Co., Inc. and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-Suicide Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Suicide Drug Market by Company
Allergan plc
H. Lundbeck A/S
NeuroRx, Inc.
AstraZeneca plc
GlaxoSmithkline plc
Pfizer, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Johnson & Johnson
Anti-Suicide Drug Segment by Type
Anti-Depressants and Anti-Anxiety Drugs
Antibiotic Analog
Anti-Psychotic Drugs
NMDA Antagonist
Others
Anti-Suicide Drug Segment by Application
Hospital
Clinic
Home Use
Anti-Suicide Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Suicide Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Suicide Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Suicide Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Suicide Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Suicide Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Suicide Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-Depressants and Anti-Anxiety Drugs
- Antibiotic Analog
- Anti-Psychotic Drugs
- NMDA Antagonist
- Others
Applications
- Hospital
- Clinic
- Home Use
Companies covered
- Allergan plc
- H. Lundbeck A/S
- NeuroRx, Inc.
- AstraZeneca plc
- GlaxoSmithkline plc
- Pfizer, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Suicide Drug Market Size (2021-2032)
- 2.2.2 Global Anti-Suicide Drug Sales (2021-2032)
- 2.2.3 Global Anti-Suicide Drug Market Average Price (2021-2032)
- 2.3 Anti-Suicide Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anti-Depressants and Anti-Anxiety Drugs
- 2.3.3 Antibiotic Analog
- 2.3.4 Anti-Psychotic Drugs
- 2.3.5 NMDA Antagonist
- 2.3.6 Others
- 2.4 Anti-Suicide Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Home Use
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Suicide Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Suicide Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Anti-Suicide Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Suicide Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Suicide Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Suicide Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Suicide Drug, Product Type & Application
- 3.8 Global Manufacturers of Anti-Suicide Drug, Established Date
- 3.9 Global Anti-Suicide Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Allergan plc
- 4.1.1 Allergan plc Company Information
- 4.1.2 Allergan plc Business Overview
- 4.1.3 Allergan plc Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Allergan plc Anti-Suicide Drug Product Portfolio
- 4.1.5 Allergan plc Recent Developments
- 4.2 H. Lundbeck A/S
- 4.2.1 H. Lundbeck A/S Company Information
- 4.2.2 H. Lundbeck A/S Business Overview
- 4.2.3 H. Lundbeck A/S Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 H. Lundbeck A/S Anti-Suicide Drug Product Portfolio
- 4.2.5 H. Lundbeck A/S Recent Developments
- 4.3 NeuroRx, Inc.
- 4.3.1 NeuroRx, Inc. Company Information
- 4.3.2 NeuroRx, Inc. Business Overview
- 4.3.3 NeuroRx, Inc. Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 NeuroRx, Inc. Anti-Suicide Drug Product Portfolio
- 4.3.5 NeuroRx, Inc. Recent Developments
- 4.4 AstraZeneca plc
- 4.4.1 AstraZeneca plc Company Information
- 4.4.2 AstraZeneca plc Business Overview
- 4.4.3 AstraZeneca plc Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca plc Anti-Suicide Drug Product Portfolio
- 4.4.5 AstraZeneca plc Recent Developments
- 4.5 GlaxoSmithkline plc
- 4.5.1 GlaxoSmithkline plc Company Information
- 4.5.2 GlaxoSmithkline plc Business Overview
- 4.5.3 GlaxoSmithkline plc Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithkline plc Anti-Suicide Drug Product Portfolio
- 4.5.5 GlaxoSmithkline plc Recent Developments
- 4.6 Pfizer, Inc.
- 4.6.1 Pfizer, Inc. Company Information
- 4.6.2 Pfizer, Inc. Business Overview
- 4.6.3 Pfizer, Inc. Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer, Inc. Anti-Suicide Drug Product Portfolio
- 4.6.5 Pfizer, Inc. Recent Developments
- 4.7 Eli Lilly and Company
- 4.7.1 Eli Lilly and Company Company Information
- 4.7.2 Eli Lilly and Company Business Overview
- 4.7.3 Eli Lilly and Company Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Eli Lilly and Company Anti-Suicide Drug Product Portfolio
- 4.7.5 Eli Lilly and Company Recent Developments
- 4.8 Merck & Co., Inc.
- 4.8.1 Merck & Co., Inc. Company Information
- 4.8.2 Merck & Co., Inc. Business Overview
- 4.8.3 Merck & Co., Inc. Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck & Co., Inc. Anti-Suicide Drug Product Portfolio
- 4.8.5 Merck & Co., Inc. Recent Developments
- 4.9 Johnson & Johnson
- 4.9.1 Johnson & Johnson Company Information
- 4.9.2 Johnson & Johnson Business Overview
- 4.9.3 Johnson & Johnson Anti-Suicide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Johnson & Johnson Anti-Suicide Drug Product Portfolio
- 4.9.5 Johnson & Johnson Recent Developments
5 Global Anti-Suicide Drug Market Scenario by Region
- 5.1 Global Anti-Suicide Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Suicide Drug Sales by Region: 2021-2032
- 5.2.1 Global Anti-Suicide Drug Sales by Region: 2021-2026
- 5.2.2 Global Anti-Suicide Drug Sales by Region: 2027-2032
- 5.3 Global Anti-Suicide Drug Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Suicide Drug Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Suicide Drug Revenue by Region: 2027-2032
- 5.4 North America Anti-Suicide Drug Market Facts & Figures by Country
- 5.4.1 North America Anti-Suicide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Suicide Drug Sales by Country (2021-2032)
- 5.4.3 North America Anti-Suicide Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-Suicide Drug Market Facts & Figures by Country
- 5.5.1 Europe Anti-Suicide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Suicide Drug Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Suicide Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-Suicide Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Suicide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Suicide Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Suicide Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Suicide Drug Market Facts & Figures by Country
- 5.7.1 South America Anti-Suicide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Suicide Drug Sales by Country (2021-2032)
- 5.7.3 South America Anti-Suicide Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-Suicide Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Suicide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Suicide Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Suicide Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-Suicide Drug Sales by Type (2021-2032)
- 6.1.1 Global Anti-Suicide Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Anti-Suicide Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Suicide Drug Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Suicide Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Suicide Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Suicide Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Suicide Drug Sales by Application (2021-2032)
- 7.1.1 Global Anti-Suicide Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Anti-Suicide Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Suicide Drug Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Suicide Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Suicide Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Suicide Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Suicide Drug Value Chain Analysis
- 8.1.1 Anti-Suicide Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Suicide Drug Production Mode & Process
- 8.2 Anti-Suicide Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Suicide Drug Distributors
- 8.2.3 Anti-Suicide Drug Customers
9 Global Anti-Suicide Drug Analyzing Market Dynamics
- 9.1 Anti-Suicide Drug Industry Trends
- 9.2 Anti-Suicide Drug Industry Drivers
- 9.3 Anti-Suicide Drug Industry Opportunities and Challenges
- 9.4 Anti-Suicide Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst